Day One Biopharmaceuticals Inc (DAWN)

Currency in USD
5.78
-1.11(-16.06%)
Real-time Data·
DAWN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
Trading near 52-week Low
DAWN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.646.09
52 wk Range
5.6416.76
Key Statistics
Prev. Close
6.88
Open
5.95
Day's Range
5.64-6.09
52 wk Range
5.64-16.76
Volume
7.2M
Average Volume (3m)
1.47M
1-Year Change
-48.11%
Book Value / Share
4.73
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DAWN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
26.25
Upside
+354.15%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Day One Biopharmaceuticals Inc Company Profile

Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company’s lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Day One Biopharmaceuticals Inc Earnings Call Summary for Q2/2025

  • Q2 2025 revenue grew 10% to $33.6M, with full-year guidance of $140-150M implying 150% YoY growth
  • Ogemda gained traction with 1,000+ prescriptions; European expansion planned with potential EMA approval by mid-2026
  • Strong financial position with $453M cash, no debt, and 95% gross profit margin; stock up 2.15% in aftermarket trading
  • Operating expenses decreased 5% QoQ to $68.9M; company focused on Ogemda and discontinued VRK1 program
  • CEO emphasized strategic focus and capitalization; CCO highlighted Ogemda's untapped market potential
Last Updated: 05/08/2025, 22:40
Read Full Transcript

Compare DAWN to Peers and Sector

Metrics to compare
DAWN
Peers
Sector
Relationship
P/E Ratio
−7.3x−1.8x−0.5x
PEG Ratio
−0.14−0.070.00
Price/Book
1.5x2.9x2.6x
Price / LTM Sales
3.7x64.4x3.3x
Upside (Analyst Target)
292.4%305.7%42.8%
Fair Value Upside
Unlock10.9%6.5%Unlock

Analyst Ratings

8 Buy
1 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 26.25
(+354.15% Upside)

Earnings

Latest Release
Aug 05, 2025
EPS / Forecast
-0.29 / -0.351
Revenue / Forecast
33.91M / 35.56M
EPS Revisions
Last 90 days

DAWN Income Statement

People Also Watch

16.21
SRPT
-3.22%
3.50
RLAY
-0.99%
6.13
KURA
-3.70%
11.27
DYN
+7.64%

FAQ

What Stock Exchange Does Day One Biopharmaceuticals Trade On?

Day One Biopharmaceuticals is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Day One Biopharmaceuticals?

The stock symbol for Day One Biopharmaceuticals is "DAWN."

What Is the Day One Biopharmaceuticals Market Cap?

As of today, Day One Biopharmaceuticals market cap is 579.79M.

What Is Day One Biopharmaceuticals's Earnings Per Share (TTM)?

The Day One Biopharmaceuticals EPS (TTM) is -0.71.

When Is the Next Day One Biopharmaceuticals Earnings Date?

Day One Biopharmaceuticals will release its next earnings report on 09 Nov 2025.

From a Technical Analysis Perspective, Is DAWN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Day One Biopharmaceuticals Stock Split?

Day One Biopharmaceuticals has split 0 times.

How Many Employees Does Day One Biopharmaceuticals Have?

Day One Biopharmaceuticals has 181 employees.

What is the current trading status of Day One Biopharmaceuticals (DAWN)?

As of 06 Aug 2025, Day One Biopharmaceuticals (DAWN) is trading at a price of 5.78, with a previous close of 6.88. The stock has fluctuated within a day range of 5.64 to 6.09, while its 52-week range spans from 5.64 to 16.76.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.